| More

Outcome after Intravenous Thhrombolysis in patients with Acute Ischemic Stroke

Views: 339 Downloads: 350
Evagelia Mallisova, Helen Dokoutsidou, Antonia Kalogianni, Georgios Vasilopoulos (https://orcid.org/0000-0001-7753-1553)
Evagelia Mallisova, Helen Dokoutsidou, Antonia Kalogianni, Georgios Vasilopoulos

Abstract


 

Introduction: Vascular disorders represent a major cause of mortality worldwide, with ischemic stroke to be the second cause of mortality, after coronary artery disease.
Aim: The aim of the present review was to investigate the contribution of thrombolysis in the outcome of patients with ischemic stroke.

Material and Method: This is a systemic review of the literature. The sources of the literature were the databases EBSCO HOST, Elsevier Science Direct, PubMed, Medline, CINAHL, and Google Scholar.No time limit was set. The

following keywords were used: ischemic stroke, thrombolysis, infarction, outcome, time window, side effects, benefits, alteplase, etiology, diagnosis, treatment.
Results: Three multicenter studies were found to meet the inclusion criteria, the NINDS trial, the ECASS II and the STARS. Thrombolysis in ischemic stroke has been associated with a significantly lower mortality, fewer intracranial hemorrhages and improved neurological outcome when administered in less than 3 hours.

Conclusions: The therapeutic benefits of alteplase reduced with time, while it has been determined that after 4.5 hours from the onset of symptoms of ischemic stroke has a significant benefit.

 

Keywords


Thrombolysis; alteplase; stroke; side effects

Full Text:

PDF

References


lobal burden of stroke, healthy years of life lost to stroke. Διαθέσιμοαπό: http://www.who.int/cardiovascular_diseases/e n/cvd_atlas_15_burden_stroke.pdf. Πρόσβασητην: 3/9/2016.

Rothwell PM, Coull AJ, Giles MF, Howard SC, Silver LE, Bull LM, et al. Change in stroke incidence, mortality, case-fatality, severity, and risk factors in Oxfordshire, UK from 1981 to 2004 (Oxford Vascular Study). Lancet 2004;363(9425):1925-33.

Lyden PD, Madden KP, Clark WM, Sasse KC, Zivin JA. Incidence of cerebral hemorrhage after treatment with tissue plasminogen activator or streptokinase following embolic stroke in rabbits [corrected]. Stroke 1990;21(11):1589-93.

European Agency for the Evaluation of Medicinal Products. Summary information on a referral opinion following an arbitration persuant to article 29 of directive 2001/83/EC for Actilyse (dated 21 November,2002, CPMP/3346/02-EN), prepared by the Committee for proprietary medicinal products (CPMP) for the European Agency for the Evaluation of Medicinal Products. Διαθέσιμο από: http://www.ema.europa.eu/docs/en_GB/docu ment_library/Referrals_document/Actilyse_29/ WC500010327.pdf. Πρόσβαση την 10/9/2016.

Brekenfeld C, Remonda L, Nedeltchev K, v Bredow F, Ozdoba C, Wiest R, et al. Endovascular neuroradiological treatment of acute ischemic stroke, techniques and results in 350 patients. Neurol Res 2005;27 Suppl 1:S29- 35.

Hacke W, Albers G, Al-Rawi Y, Bogousslavsky J, Davalos A, Eliasziw M, et al. The Desmoteplase in Acute Ischemic Stroke Trial (DIAS), a phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke 2005;36(1):66-73.

MAST-I. Randomised controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischaemic stroke. Multicentre Acute Stroke Trial-Italy (MAST-I) Group. Lancet 1995;346(8989):1509-14.

Σελίδα 12

ΤΟΜΟΣ 4, ΤΕΥΧΟΣ 1 (ΙΑΝΟΥΑΡΙΟΣ – ΜΑΡΙΤΟΣ 2018)

HEALTH AND RESEARCH JOURNAL HRJ

Furlan AJ. (1997). NINDS: stroke proceedings: Furlan overview. Διαθέσιμο από: http://www.ninds.nih.gov/news_and_events/pr oceedings/stroke_proceedings/furlan.html. Πρόσβαση την 10/9/2016να γραφτεί σωστά .

Albers GW, Bates VE, Clark WM, Bell R, Verro P, Hamilton SA. Intravenous tissue-type plasminogen activator for treatment of acute stroke: the Standard Treatment with Alteplase to Reverse Stroke (STARS) study. JAMA. 2000 Mar

1;283(9)Hacke W, Kaste M, Bluhmki E, Brozman M, Dávalos A, Guidetti D, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 2008;359(13):1317-29.

Wahlgren N, Ahmed N, Davalos A, Ford GA, Grond M, Hacke W, et al. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke- Monitoring Study (SITS-MOST), an observational study. Lancet 2007;369(9558):275-82.

plasminogen activator for acute ischemic stroke.

N Engl J Med. 1995 Dec 14;333(24):1581-7.

Chapman KM, Woolfenden AR, Graeb D, Johnston DC, Beckman J, Schulzer M, et al. Intravenous tissue plasminogen activator for acute ischemic stroke, A Canadian hospital's

experience. Stroke 2000;31(12):2920-4.

Koennecke HC, Nohr R, Leistner S, Marx P. Intravenous tPA for ischemic stroke team performance over time, safety, and efficacy in a single-center, 2-year experience. Stroke

;32(5):1074-8.

Wahlgren N, Ahmed N, Davalos A, Hacke W,

Millán M, Muir K, et al. Thrombolysis with alteplase 3-4.5 h after acute ischaemic stroke (SITS-ISTR), an observational study. Lancet. 2008;372(9646):1303-9.

Chiu D, Krieger D, Villar-Cordova C, Kasner SE, Morgenstern LB, Bratina PL, et al. Intravenous tissue plasminogen activator for acute ischemic stroke, feasibility, safety, and efficacy in the first year of clinical practice. Stroke 1998;29(1):18-

Katzan IL, Furlan AJ, Lloyd LE, Frank JI, Harper 22.

DL, Hinchey JA, et al. Use of tissue-type plasminogen activator for acute ischemic stroke, the Cleveland area experience. JAMA 2000;283(9):1151-8.

Rehan V, Haider AZ, Alvaro RE, Nowaczyk B, Cates DB, Kwiatkowski K, et al. The biphasic ventilatory response to hypoxia in preterm infants is not due to a decrease in metabolism. Pediatric Pulmonology 1996;22(5):287-94.

National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue

Grond M, Stenzel C, Schmulling S, Rudolf J, Neveling M, Lechleuthner A, et al. Early intravenous thrombolysis for acute ischemic stroke in a community-based approach. Stroke 1998;29(8):1544-9.

Egan R, Lutsep HL, Clark WM, Quinn J, Kearns K, Lockfeld A, et al. Open label tissue plasminogen activator for stroke, the Oregon experience. J Stroke Cerebrovasc Dis 1999; 8(5):287-90.

Katzan IL, Hammer MD, Furlan AJ, Hixson ED, Nadzam DM. Quality improvement and tissue- type plasminogen activator for acute ischemic

Σελίδα 13

ΤΟΜΟΣ 4, ΤΕΥΧΟΣ 1 (ΙΑΝΟΥΑΡΙΟΣ – ΜΑΡΙΤΟΣ 2018) HEALTH AND RESEARCH JOURNAL HRJ

stroke, a Cleveland update. Stroke

;34(3):799-800.

Chapman KM, Woolfenden AR, Graeb D,

Johnston DC, Beckman J, Schulzer M, et al. Intravenous tissue plasminogen activator for acute ischemic stroke, A Canadian hospital's experience. Stroke 2000;31(12):2920-4.

Barber PA, Zhang J, Demchuk AM, Hill MD, Buchan AM. Why are stroke patients excluded from TPA therapy? An analysis of patient eligibility. Neurology 2001;56(8):1015-20.

Koennecke HC, Nohr R, Leistner S, Marx P. Intravenous tPA for ischemic stroke team performance over time, safety, and efficacy in a

single-center, 2-year experience. Stroke 2001;32(5):1074-8.

Wahlgren N, Ahmed N, Davalos A, Hacke W, Millán M, Muir K, et al. Thrombolysis with alteplase 3-4.5 h after acute ischaemic stroke (SITS-ISTR), an observational study. Lancet 2008;372(9646):1303-9.


Refbacks

  • There are currently no refbacks.


Health and Research Journal